While there was a numerical reduction in the incidence of MI (aHR, 0.88; 95% CI 0.66–1.18, P = 0.404) and stroke (aHR, 0.86; 95% CI 0.64–1.15, p = 0.299) among GLP-1 RAs users, these differences did not reach statistical significance (Fig. 2 ).
← all excerpts
Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients.
1
—
—